Dendrimers can improve efficacy of drugs by enabling a longer half-life, extended release and targetting of diseased tissue (in particular cancerous tissue).
Docetaxel is a leading chemotherapy used to treat a range of solid tumours. Starpharma compared the performance of docetaxel to a DEP® docetaxel formulation in a breast cancer model in mice. The results of the study showed that Starpharma’s DEP® docetaxel formulation demonstrated a significant enhancement of anticancer activity when compared to docetaxel alone. 60% of the mice treated with Starpharma’s DEP® docetaxel formulation had no evidence of tumours at 94 days whereas with docetaxel alone significant tumour regrowth was observed in all animals.